Sai Life Sciences Q1FY26 Revenue Rises 77 Per Cent YoY

08 Aug 2025 CW Team

Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.

Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.

Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.

Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.

To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.

Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”

CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”

Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO), reported strong financial results for the first quarter of fiscal year 2026, led by significant growth in its CDMO segment.Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Real Estate

07 Aug 2026

BXB Estates Sets AED 110 Million Jumeirah Golf Estates Record

BXB Estates has completed an AED 110 million residential transaction at Jumeirah Golf Estates, setting a new sales record for the prestigious Dubai residential community.Negotiated by Alfie Tabrez, Managing Partner of BXB Estates, the deal surpassed the previous record of AED 58 million for a completed ready villa in the development.The six-bedroom residence offers 21,714 sq ft of built-up space on a 15,873-sq-ft plot. It features nine bathrooms, four living lounges, a home office, bar lounge, private cinema and rooftop terrace.The property also includes a dedicated wellness area comprising a ..

Infrastructure Urban

07 Aug 2026

SECR Floats Rs 6,019 Mn EPC Tender For Paradol Nagpur Link

South East Central Railway (SECR) has invited bids for an Engineering, Procurement and Construction (EPC) contract to build a new broad gauge single line between Paradol Takeoff Point and Nagpur Road Station in Chhattisgarh. The contract carries an estimated cost of Rs 6,019.0 mn and requires an earnest money deposit of Rs 120.4 mn. The work is framed as an EPC assignment intended to strengthen regional rail infrastructure. The tender, issued under number CAO-C-BSP-26-27-15, specifies a completion period of 730 days and a bid validity of 180 days. Two pre-bid meetings are scheduled for 24 Augu..

Infrastructure Transport

07 Aug 2026

Indian Railways Reports Nine Per Cent Rise In July Freight Loading

Indian Railways handled 141.3 million tonnes (141.3 mn t) of freight in July, marking a rise of nine per cent year on year. Freight loading maintained a positive trajectory across the network compared with the same month last year. Passenger traffic also increased in July, contributing to higher overall network utilisation. The July outcome continued a pattern of steady monthly gains, reflecting gradual improvement in industrial and logistics activity. The growth in freight volumes reflected stronger demand across multiple sectors and improvements in logistics and train turnarounds. Enhanced r..